|
Title
|
|
|
|
Insights into GABA(A)ergic system deficits in fragile X syndrome lead to clinical trials
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| An increasing number of studies implicate the GABA(A)ergic system in the pathophysiology of the fragile X syndrome, a frequent cause of intellectual disability and autism. Animal models have proven invaluable in unravelling the molecular mechanisms underlying the disorder. Multiple defects in this inhibitory system have been identified in Fmr1 knockout mice, including altered expression of various components, aberrant GABA(A) receptor-mediated signalling, altered GABA concentrations and anatomical defects in GABAergic neurons. Aberrations compatible with those described in the mouse model were detected in dfmr1 deficient Drosophila melanogaster, a validated fly model for the fragile X syndrome. Treatment with drugs that ameliorate the GABA(A)ergic deficiency in both animal models have demonstrated that the GABA(A) receptor is a promising target for the treatment of fragile X patients. Based on these preclinical studies, clinical trials in patients have been initiated. (C) 2014 Elsevier Ltd. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Neuropharmacology. - Oxford, 1970, currens
|
|
|
Publication
|
|
|
|
Oxford
:
Pergamon-elsevier science ltd
,
2015
|
|
|
ISSN
|
|
|
|
0028-3908
[print]
1873-7064
[online]
|
|
|
DOI
|
|
|
|
10.1016/J.NEUROPHARM.2014.06.028
|
|
|
Volume/pages
|
|
|
|
88
(2015)
, p. 48-54
|
|
|
ISI
|
|
|
|
000345949500006
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|